NCT01963663View on ClinicalTrials.gov

Metformin and Pioglitazone Effects on YKL-40 Concentrations in Type 2 Diabetes Patients

NACompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

April 30, 2013

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Metformin

metformin 1000 mg daily in two divided doses of 500 mg tablets

DRUG

Pioglitazone

pioglitazone 30 mg daily in two divided doses of 15 mg tablets

Trial Locations (1)

13145-784

Diabetes Clinic, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran

All Listed Sponsors
lead

Tehran University of Medical Sciences

OTHER

NCT01963663 - Metformin and Pioglitazone Effects on YKL-40 Concentrations in Type 2 Diabetes Patients | Biotech Hunter | Biotech Hunter